Literature DB >> 11389093

Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium.

R L Arnett-Mansfield1, A deFazio, G V Wain, R C Jaworski, K Byth, P A Mote, C L Clarke.   

Abstract

The nuclear receptor for the female hormone progesterone (PR) is widely expressed in uterine cancer. PR is expressed as two proteins (PRA and PRB) with different functions, and in vitro evidence reveals PRA to inhibit PRB function, so the cellular ratio of PRA:PRB is likely to be an important determinant of progesterone action. The relative expression of PRA and B and their involvement in the pathogenesis of endometrial cancer is not known. The aims of this study were to determine PRA and B expression by dual immunofluorescent histochemistry in endometrial adenocarcinomas compared with expression in normal and hyperplastic glands, and to correlate expression in tumors with clinical features including grade. Significantly lower PR levels were found in tumors compared with normal glands and areas of complex atypical hyperplasia within the same specimen. The normal glands expressed both of the isoforms at similar levels, whereas there was increased predominance of one isoform in hyperplastic areas and in tumors, which suggested that the loss of coordinated expression of PR isoforms was an early event in tumor progression. The majority of tumors [27 (58%) of 46] expressed only one PR isoform, and the proportion expressing either PRA or B was the same [14 (30%) of 46, and 13 (28%) of 46, respectively]. One-half of all tumors ([23 (50%) of 46] expressed either PRA only or a predominance of PRA, and a few tumors [10 (22%) of 46] expressed comparable levels of PRA and B. Similar levels of PRA and B were noted only in FIGO grade 1 tumors, whereas higher grades (2 and 3) were associated with a predominance of one isoform. In summary, expression of only one PR isoform was common in endometrial cancers, which indicates that the decreased PR levels observed in these cancers arise from the loss of one PR isoform. Expression of a single PR isoform was associated with higher clinical grade, which suggests a relationship between the loss of PR isoform expression and features of poorer prognosis. Disruption of relative PR isoform expression was observed in complex atypical hyperplasia, which suggests that early alterations in the ratio of PRA:PRB may precede and/or be implicated in the development of endometrial adenocarcinoma. Alterations in the ratio of PR isoform expression are likely to cause disordered regulation of target genes, resulting in altered progestin action in the uterus, and this may be involved in the pathogenesis of endometrial cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11389093

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

Review 1.  Progesterone receptors in mammary gland development and tumorigenesis.

Authors:  Orla M Conneely; Biserka M Jericevic; John P Lydon
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-04       Impact factor: 2.673

2.  A novel loss-of-function mutation in TP53 in an endometrial cancer cell line and uterine papillary serous carcinoma model.

Authors:  Zhihe Liu; Guanghua Wan; Christopher Heaphy; Marco Bisoffi; Jeffrey K Griffith; Chien-An A Hu
Journal:  Mol Cell Biochem       Date:  2006-11-21       Impact factor: 3.396

3.  cAMP-Response Element-Binding 3-Like Protein 1 (CREB3L1) is Required for Decidualization and its Expression is Decreased in Women with Endometriosis.

Authors:  J I Ahn; J-Y Yoo; T H Kim; Y I Kim; S D Ferguson; A T Fazleabas; S L Young; B A Lessey; J Y Ahn; J M Lim; J-W Jeong
Journal:  Curr Mol Med       Date:  2016       Impact factor: 2.222

4.  p38 and p42/44 MAPKs differentially regulate progesterone receptor A and B isoform stabilization.

Authors:  Junaid A Khan; Larbi Amazit; Catherine Bellance; Anne Guiochon-Mantel; Marc Lombès; Hugues Loosfelt
Journal:  Mol Endocrinol       Date:  2011-08-04

Review 5.  Progesterone receptor signaling in the initiation of pregnancy and preservation of a healthy uterus.

Authors:  Margeaux Wetendorf; Francesco J DeMayo
Journal:  Int J Dev Biol       Date:  2014       Impact factor: 2.203

6.  Detection of progesterone receptor forms A and B by immunohistochemical analysis.

Authors:  P A Mote; J F Johnston; T Manninen; P Tuohimaa; C L Clarke
Journal:  J Clin Pathol       Date:  2001-08       Impact factor: 3.411

7.  Progesterone receptor-B induction of BIRC3 protects endometrial cancer cells from AP1-59-mediated apoptosis.

Authors:  Nikki L Neubauer; Erin C Ward; Parin Patel; Zhenxiao Lu; Irene Lee; Leen J Blok; Payman Hanifi-Moghaddam; Julian Schink; J Julie Kim
Journal:  Horm Cancer       Date:  2011-06       Impact factor: 3.869

8.  Progesterone receptor B recruits a repressor complex to a half-PRE site of the estrogen receptor alpha gene promoter.

Authors:  F De Amicis; S Zupo; M L Panno; R Malivindi; F Giordano; I Barone; L Mauro; S A W Fuqua; S Andò
Journal:  Mol Endocrinol       Date:  2009-01-15

9.  The Synergistic Effect of Conditional Pten Loss and Oncogenic K-ras Mutation on Endometrial Cancer Development Occurs via Decreased Progesterone Receptor Action.

Authors:  Tae Hoon Kim; Jinrong Wang; Kevin Y Lee; Heather L Franco; Russell R Broaddus; John P Lydon; Jae-Wook Jeong; Francesco J Demayo
Journal:  J Oncol       Date:  2009-10-27       Impact factor: 4.375

Review 10.  Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression.

Authors:  Katherine M Scarpin; J Dinny Graham; Patricia A Mote; Christine L Clarke
Journal:  Nucl Recept Signal       Date:  2009-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.